Comparative Pharmacology
Head-to-head clinical analysis: EDECRIN versus FUROSCIX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EDECRIN versus FUROSCIX.
EDECRIN vs FUROSCIX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ethacrynic acid inhibits the Na-K-Cl cotransporter (NKCC2) in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium, leading to diuresis.
Furosemide inhibits the Na-K-2Cl cotransporter (NKCC2) in the thick ascending limb of the loop of Henle, reducing sodium and chloride reabsorption, leading to increased diuresis.
Oral: 50-100 mg once or twice daily, maximum 400 mg/day. IV: 50 mg (0.5 mg/kg) once, may repeat once at 2-hour intervals if needed.
80 mg subcutaneously once daily via prefilled syringe. Maximum 80 mg/day. Administer as an adjunct to oral diuretic therapy.
None Documented
None Documented
Terminal elimination half-life is 2-4 hours; prolonged in renal impairment (up to 30 hours) and in heart failure.
Terminal half-life 1.5-2 hours in healthy; prolonged to 4-8 hours in renal impairment (CrCl <30 mL/min) and 9-19 hours in anuria
Approximately 60-70% excreted unchanged in urine via glomerular filtration and tubular secretion; remaining 30-40% eliminated via biliary/fecal route.
Renal (60-80% unchanged; glucuronide metabolites account for 10-20%); biliary/fecal (<10%)
Category C
Category C
Loop Diuretic
Loop Diuretic